RICHMOND, Calif., May 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the presentation of preclinical data from its ZFP Therapeutic(TM) program in nerve regeneration at the Fourteenth Annual Conference of the American Society for Neural Therapy and Repair. The data generated, in a model of spinal cord injury (SCI), demonstrate that treatment of the spinal cord at the time of injury with a VEGF ZFP TF had a statistically significant effect on recovery of hind-limb function as well as a number of other measures of nerve integrity and health.
